| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2001 | WO2001032160A2 Modification of cholesterol concentrations with citrus phytochemicals |
| 05/10/2001 | WO2001032159A2 Methods and formulations for the treatment of infectious bursal disease in avian subjects |
| 05/10/2001 | WO2001032158A2 Pharmaceutical composition comprising a combination of metformin and another antidiabetic agent |
| 05/10/2001 | WO2001032157A2 Pharmaceutical composition comprising a combination of metformin and glibenclamide |
| 05/10/2001 | WO2001032156A2 Methods for treating fibroproliferative diseases |
| 05/10/2001 | WO2001032155A2 Use of egfr tyrosine kinase inhibitors for treating breast cancer |
| 05/10/2001 | WO2001032154A2 Use of treosulfan for patient conditioning before bone marrow or blood stem cell transplantation |
| 05/10/2001 | WO2001032153A2 Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues |
| 05/10/2001 | WO2001032149A1 Osmotic controlled release drug delivery device |
| 05/10/2001 | WO2001032148A1 Controlled release hydrocodone formulations |
| 05/10/2001 | WO2001032145A1 Method of cancer treatment |
| 05/10/2001 | WO2001032144A1 Dry powder compositions having improved dispersivity |
| 05/10/2001 | WO2001032130A2 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | WO2001032128A2 Human chemokine beta-13 |
| 05/10/2001 | WO2001032127A2 Method and compositions for treating pulmonary diseases |
| 05/10/2001 | WO2001032125A2 Apparatus and process for preparing crystalline particles |
| 05/10/2001 | WO2001032115A1 Transdermal administration of huperzine |
| 05/10/2001 | WO2001032038A1 Fibrous-liponutritional complexes and compositions containing them |
| 05/10/2001 | WO2001032036A1 Cholesterol reducing stanol compositions, preparation and method of use |
| 05/10/2001 | WO2001032031A2 Cholesterol reducing sterol compositions, preparation and method of use |
| 05/10/2001 | WO2001032030A1 Food or veterinary composition for domestic carnivores containing free tyrosine |
| 05/10/2001 | WO2001032029A2 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 05/10/2001 | WO2001019378A3 Solid lipid formulations comprising an inhibitor of lipases and a fatty acid ester of polyols |
| 05/10/2001 | WO2001017959A3 Vitronectin receptor antagonists |
| 05/10/2001 | WO2001016306A3 Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| 05/10/2001 | WO2001012175A8 Uses compositions for treating or preventing sleep disturbances using very low doses of cyclobenzaprine |
| 05/10/2001 | WO2001008505A3 Methods for suppressing appetite and enhancing exercise and recovery |
| 05/10/2001 | WO2001007418A3 Ceramide analogs, process for their preparation and their use as antitumor agents |
| 05/10/2001 | WO2001005393A3 Method for treating chronic pain using mek inhibitors |
| 05/10/2001 | WO2001004122A3 New 2,3-benzodiazepine derivatives |
| 05/10/2001 | WO2001001922A3 Use of substance p antagonists for the treatment of adenocarcinoma |
| 05/10/2001 | WO2001000652A3 11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, METHOD FOR THEIR PRODUCTION, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 11β LONG-CHAIN SUBSTITUTED ESTRATRIENES, AND THEIR USE FOR PRODUCING MEDICAMENTS |
| 05/10/2001 | WO2001000191A3 Use of fosphenytion for the treatment of acute neuropathic pain |
| 05/10/2001 | WO2001000183A3 COMBINATION OF MTP INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS AND THE USE THEREOF IN MEDICAMENTS |
| 05/10/2001 | WO2000078778A3 C-pyrazole a2a receptor agonists |
| 05/10/2001 | WO2000077207A3 Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto |
| 05/10/2001 | WO2000077035A3 Novel potassium channels and genes encoding these potassium channels |
| 05/10/2001 | WO2000076488A3 Use of a ppar agonist for treating type 1 diabetes |
| 05/10/2001 | WO2000073276A3 Carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists |
| 05/10/2001 | WO2000072885A3 Methods of inducing regulated pancreatic hormone production in non-pancreatic islet tissues |
| 05/10/2001 | WO2000072865A3 Antifungal combination use |
| 05/10/2001 | WO2000067800A3 Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates |
| 05/10/2001 | WO2000064488A3 Somatic transgene immunization and related methods |
| 05/10/2001 | WO2000063241A3 Methods and compositions for modulating an immune response |
| 05/10/2001 | WO2000047720A3 Pancreatic progenitor cells, methods and uses related thereto |
| 05/10/2001 | WO2000034334A9 DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF |
| 05/10/2001 | WO2000033888A9 Prodrug compounds and process for preparation thereof |
| 05/10/2001 | WO2000016745A3 Micronised pharmaceutical compositions |
| 05/10/2001 | WO1999002514A3 Epothilone derivatives |
| 05/10/2001 | US20010001106 Preparing D-mannitol having a specific surface area of not less than about 1 m2/g which comprises treating delta form D-mannitol crystals with a water-soluble solvent followed by drying |
| 05/10/2001 | US20010001104 Thienopyridine compounds, their production and use |
| 05/10/2001 | US20010001101 Anti-fibroproliferative agents, treatment of pulmonary fibrosis, renal fibrosis, cardiac fibrosis, arteriosclerosis or treating scar tissue formation following injury |
| 05/10/2001 | US20010001100 For treating narrow-angle glaucoma, Alzheimer's disease, as well as alcohol and nicotine dependence |
| 05/10/2001 | US20010001099 For treatment of prostate cancer and benign prostatic hypertrophy |
| 05/10/2001 | US20010001097 Stress-follower circuit configuration |
| 05/10/2001 | US20010001040 Alteration of macrophage-induced T cell suppression or concentration by the selective elimination or increase of tryptophan by administering an enzyme inhibitor of indole-amino 2,3-deoxygenase; viricides; abortion; fertility; |
| 05/10/2001 | DE19953775A1 Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften Drug combinations with insecticidal and acaricidal properties |
| 05/10/2001 | DE19953414A1 Imidazopyridinderivate als Phospodiesterase VII-Hemmer Imidazopyridine derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953025A1 Pyrrolderivate als Phosphodiesterase VII-Hemmer Pyrrole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19953024A1 Isoxazolderivate als Phosphodiesterase VII-Hemmer Isoxazole derivatives as phosphodiesterase VII inhibitor |
| 05/10/2001 | DE19950686A1 New multifunctional cholic acid spacer is used with cis-platinum anolog in drug targeting |
| 05/10/2001 | DE19950483A1 Verfahren zur Herstellung von 3-Nitryloxy-2,2-bis(nitryloxymethyl)-propanal A process for the preparation of 3-nitryloxy-2,2-bis (nitryloxymethyl) -propanal |
| 05/10/2001 | CA2390182A1 Novel human transporter proteins and polynucleotides encoding the same |
| 05/10/2001 | CA2390077A1 Composite nanospheres and their conjugates with biomolecules |
| 05/10/2001 | CA2390025A1 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 05/10/2001 | CA2389973A1 Method of treating amyloid beta precursor disorders |
| 05/10/2001 | CA2389931A1 Antidiabetic formulation and method |
| 05/10/2001 | CA2389908A1 Novel apparatus and process for preparing crystalline particles |
| 05/10/2001 | CA2389865A1 Transdermal administration of huperzine |
| 05/10/2001 | CA2389807A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | CA2389778A1 Oligobenzimidazole derivatives and their use as dna transfection agents |
| 05/10/2001 | CA2389773A1 Activators of soluble guanylate cyclase |
| 05/10/2001 | CA2389751A1 Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same |
| 05/10/2001 | CA2389704A1 Compositions comprising edible oils and phytosterols and/or phytostanols substantially dissolved therein, method of making the same, and use thereof in treating or preventing cardiovascular disease, and its underlying conditions |
| 05/10/2001 | CA2389703A1 Indeno-, naphtho-, and benzocyclohepta-dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments |
| 05/10/2001 | CA2389666A1 Production of polymorphic forms i and ii of finasteride by complexation with group i or ii metal salts |
| 05/10/2001 | CA2389661A1 Product comprising at least a no synthase inhibiting substance associated with at least a phospholipase a2 inhibiting substance |
| 05/10/2001 | CA2389655A1 Use of nitric oxide for the treatment of airway constriction |
| 05/10/2001 | CA2389645A1 Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors |
| 05/10/2001 | CA2389643A1 Use of dopamine-d3 receptor agonists for the therapy of salt-dependent hypertension |
| 05/10/2001 | CA2389623A1 Method of treating benign forgetfulness |
| 05/10/2001 | CA2389616A1 Liver selective therapy |
| 05/10/2001 | CA2389605A1 Cholesterol reducing stanol compositions, preparation and method of use |
| 05/10/2001 | CA2389575A1 Modulation of neuroendocrine differentiation by protein 25.1 |
| 05/10/2001 | CA2389439A1 Nonpeptide substituted benzothiazepines as vasopressin antagonists |
| 05/10/2001 | CA2389415A1 Novel genes tzap7/a, tzap7/b and tzap7 involved in t cell activation and uses thereof |
| 05/10/2001 | CA2389377A1 Substituted 5-benzyl-2,4-diaminopyrimidines |
| 05/10/2001 | CA2389335A1 Gene expression directed by a super-psa promoter |
| 05/10/2001 | CA2389312A1 Heterocyclic cytotoxic agents |
| 05/10/2001 | CA2389293A1 Method for administering a phosphodiesterase 4 inhibitor |
| 05/10/2001 | CA2389259A1 2-benzyl and 2-heteroaryl benzimidazole nmda/nr2b antagonists |
| 05/10/2001 | CA2389237A1 Abc1 modulation for the modulation of cholesterol transport |
| 05/10/2001 | CA2389236A1 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 05/10/2001 | CA2389234A1 2-cyclohexyl benzimidazole nmda/nr2b antagonists |
| 05/10/2001 | CA2389229A1 Compounds having mif antagonist activity |
| 05/10/2001 | CA2389226A1 1,4 substituted piperidinyl nmda/nr2b antagonists |
| 05/10/2001 | CA2389208A1 Process for the preparation of oxyiminoalkanoic acid derivatives |
| 05/10/2001 | CA2389184A1 5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline nmda/nr2b antagonists |
| 05/10/2001 | CA2389182A1 2-aza-bicyclo¬2.2.2|octane nmda/nr2b antagonists |
| 05/10/2001 | CA2389058A1 Novel tumor suppressor gene |